4-(thiazol-2-ylcarbamoyl)benzoic acid | 851202-98-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(thiazol-2-ylcarbamoyl)benzoic acid
• 英文别名: N-thiazol-2-ylterephthalamic acid；4-(1,3-thiazol-2-ylcarbamoyl)benzoic acid
• CAS: 851202-98-7
• 化学式: C₁₁H₈N₂O₃S
• mdl: MFCD12528883
• 分子量: 248.262
• InChiKey: BCQFOIDKKOJGCI-UHFFFAOYSA-N

物化性质

• 密度：
  1.518±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(thiazol-2-ylcarbamoyl)benzoic acid 、 特戊胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 、 1,2-二氯乙烷 为溶剂， 以16%的产率得到N-(2,2-dimethylpropyl)-N'-thiazol-2-ylterephthalamide
  参考文献：
  名称：

  [EN] N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES
  [FR] DERIVES DE N-THIAZOLE-2-YLE-BENZAMIDE

  摘要：

  该发明涉及描述中的式I的N-噻唑-2-基苯甲酰衍生物，其中变量如索权中所定义。这些化合物是A2A受体配体，如拮抗剂、激动剂、反向激动剂或部分激动剂，并且在治疗神经和精神障碍中具有用处，其中A2A受体被牵涉其中。

  公开号：

  WO2005039572A1
• 作为产物：
  描述：

  4-氯甲酰基苯甲酸甲酯 在 吡啶 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 4.0h， 生成 4-(thiazol-2-ylcarbamoyl)benzoic acid
  参考文献：
  名称：

  Discovery of Phosphoric Acid Mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} Ester (Lu AA47070): A Phosphonooxymethylene Prodrug of a Potent and Selective hA_2A Receptor Antagonist

  摘要：

  The discovery and structure-activity relationship of a series of hA(2A) receptor antagonists is described. Compound 28 was selected from the series as a potent and selective compound and was shown to be efficacious in an in vivo model of Parkinson's disease. It had acceptable ADME properties; however, the low intrinsic solubility of this compound was limiting for its developability, because the oral bioavailability from dosing in suspension was significantly lower than the oral bioavailability from solution dosage. As a consequence, prodrugs of 28 were prepared with dramatically increased aqueous solubility. The prodrugs efficiently delivered 28 into systemic circulation, with no detectable levels of prodrug in plasma samples. From this investigation, we selected 32 (Lu AA47070), a phosphonooxymethylene prodrug of 28, as a drug candidate.

  DOI：

  10.1021/jm1008659

文献信息

• [EN] N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES<br/>[FR] DERIVES DE N-THIAZOLE-2-YLE-BENZAMIDE
  申请人：LUNDBECK & CO AS H

  公开号：WO2005039572A1

  公开（公告）日：2005-05-06

  The invention relates to N-thiazol-2-yl-benzamide derivatives of the formula I in the description wherein the variables are as defined in the claims. The compounds are A2A-receptor ligands, such as antagonists, agonists, reverse agonists or partial agonists, and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated.

  该发明涉及描述中的式I的N-噻唑-2-基苯甲酰衍生物，其中变量如索权中所定义。这些化合物是A2A受体配体，如拮抗剂、激动剂、反向激动剂或部分激动剂，并且在治疗神经和精神障碍中具有用处，其中A2A受体被牵涉其中。
• Aminothiazoles and aminothiadiazoles as nucleophiles in aminocarbonylation of iodobenzene derivatives
  作者：Máté Gergely、László Kollár

  DOI：10.1016/j.tet.2018.03.007

  日期：2018.4

  Various 2-, 3- and 4-substituted iodobenzenes were aminocarbonylated using aminothiazole and aminothiadiazole derivatives in palladium-catalysed reaction. The reaction is chemospecific toward the corresponding carboxamides. Consequently, the application of the above N-nucleophiles provided the N-1,3-thiazol-2-yl- and N-1,3,4-thiadiazol-2-ylcarboxamides in moderate to high yields. Due to the facile

  使用氨基噻唑和氨基噻二唑衍生物在钯催化的反应中将各种2-，3-和4-取代的碘苯氨基羰基化。该反应对相应的羧酰胺具有化学特异性。因此，上述N-亲核试剂的应用以中等至高产率提供了N -1,3-噻唑-2-基-和N -1,3,4-噻二唑-2-基甲酰胺。由于反应混合物易于后处理，在大多数情况下，分离出的产率为90％或更高。
• N-thiazol-2-yl-benzamide derivatives
  申请人：Sams Graven Anette

  公开号：US20060154974A1

  公开（公告）日：2006-07-13

  The invention relates to compounds of the formula I wherein the variables are as defined in the claims. The compounds are A 2A -receptor ligands, such as antagonists, agonists, reverse agonists or partial agonists, and are useful in the treatment of neurological and psychiatric disorders where an A 2A -receptor is implicated.

  本发明涉及公式I的化合物，其中变量如权利要求所定义。该化合物是A2A受体配体，如拮抗剂，激动剂，反向激动剂或部分激动剂，并且在治疗涉及A2A受体的神经和精神障碍方面有用。
• N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES
  申请人：Sams Anette Graven

  公开号：US20090247593A1

  公开（公告）日：2009-10-01

  The invention relates to compounds of the formula I wherein the variables are as defined in the claims. The compounds are A 2A -receptor ligands, such as antagonists, agonists, reverse agonists or partial agonists, and are useful in the treatment of neurological and psychiatric disorders where an A 2A -receptor is implicated.

  本发明涉及式I的化合物，其中变量如权利要求所定义。这些化合物是A2A受体配体，例如拮抗剂、激动剂、反向激动剂或部分激动剂，并且在治疗神经系统和精神障碍中，其中涉及到A2A受体时具有用处。
• Discovery of Phosphoric Acid Mono-{2-[(<i>E</i>/<i>Z</i>)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} Ester (Lu AA47070): A Phosphonooxymethylene Prodrug of a Potent and Selective hA_2A Receptor Antagonist
  作者：Anette G. Sams、Gitte K. Mikkelsen、Mogens Larsen、Morten Langgård、Mark E. Howells、Tenna J. Schrøder、Lise T. Brennum、Lars Torup、Erling B. Jørgensen、Christoffer Bundgaard、Mads Kreilgård、Benny Bang-Andersen

  DOI：10.1021/jm1008659

  日期：2011.2.10

  The discovery and structure-activity relationship of a series of hA(2A) receptor antagonists is described. Compound 28 was selected from the series as a potent and selective compound and was shown to be efficacious in an in vivo model of Parkinson's disease. It had acceptable ADME properties; however, the low intrinsic solubility of this compound was limiting for its developability, because the oral bioavailability from dosing in suspension was significantly lower than the oral bioavailability from solution dosage. As a consequence, prodrugs of 28 were prepared with dramatically increased aqueous solubility. The prodrugs efficiently delivered 28 into systemic circulation, with no detectable levels of prodrug in plasma samples. From this investigation, we selected 32 (Lu AA47070), a phosphonooxymethylene prodrug of 28, as a drug candidate.